Commission Delegated Regulation (EU) 2022/692 of 16 February 2022 amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures (Text with EEA relevance)
Date: 2022-02-16
Institutions: Directorate-General for Environment, European Commission
Subjects: classification, dangerous substance, environmental protection, labelling, packaging, public health, technological change








L_2022129EN.01000101.xml










3.5.2022   


EN


Official Journal of the European Union


L 129/1








            COMMISSION DELEGATED REGULATION (EU) 2022/692
of 16 February 2022
         
amending, for the purposes of its adaptation to technical and scientific progress, Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures
(Text with EEA relevance)


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (1), and in particular Article 37(5) thereof,

Whereas:







(1)


Table 3 of Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains the list of harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to that Regulation.












(2)


Proposals to introduce harmonised classification and labelling of certain substances and to update or delete the harmonised classification and labelling of certain other substances have been submitted to the European Chemicals Agency (the ‘Agency’) pursuant to Article 37 of Regulation (EC) No 1272/2008. The Committee for Risk Assessment of the Agency (RAC) adopted, after having taken account of the comments received from the parties concerned, the following opinions (2) on those proposals:






—


Opinion of 5 December 2019 concerning silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide;










—


Opinion of 4 May 2020 concerning cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate;










—


Opinion of 4 May 2020 concerning beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate;










—


Opinion of 4 May 2020 concerning acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine;










—


Opinion of 11 June 2020 concerning tellurium;










—


Opinion of 11 June 2020 concerning tellurium dioxide;










—


Opinion of 11 June 2020 concerning 2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol;










—


Opinion of 11 June 2020 concerning piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether;










—


Opinion of 11 June 2020 concerning benzophenone;










—


Opinion of 11 June 2020 concerning exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate;










—


Opinion of 11 June 2020 concerning daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid;










—


Opinion of 11 June 2020 concerning clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine;










—


Opinion of 11 June 2020 concerning fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide;










—


Opinion of 11 June 2020 concerning trichlorosilane;










—


Opinion of 11 June 2020 concerning 2-ethylhexanoic acid and its salts;










—


Opinion of 11 June 2020 concerning a reassessment at the request of the European Commission of the developmental toxicity of N-carboxymethyliminobis (ethylenenitrilo)tetra(acetic acid) (DTPA) and its pentasodium and pentapotassium salts










—


Opinion of 17 September 2020 concerning dibutyltin bis(2-ethylhexanoate);










—


Opinion of 17 September 2020 concerning dibutyltin di(acetate);










—


Opinion of 17 September 2020 concerning barium diboron tetraoxide;










—


Opinion of 17 September 2020 concerning quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone;










—


Opinion of 17 September 2020 concerning 4,4'-oxydi(benzenesulphonohydrazide);










—


Opinion of 17 September 2020 toluene-4-sulphonohydrazide;










—


Opinion of 17 September 2020 concerning theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione;










—


Opinion of 17 September 2020 concerning 1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI];










—


Opinion of 17 September 2020 concerning Bis(isocyanatomethyl)benzene; [m-XDI];










—


Opinion of 17 September 2020 concerning 2,4,6-triisopropyl-m-phenylene diisocyanate;










—


Opinion of 17 September 2020 concerning N-(2-nitrophenyl)phosphoric triamide;










—


Opinion of 17 September 2020 concerning cumene;










—


Opinion of 17 September 2020 concerning 2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate;trimethylolpropane triacrylate;










—


Opinion of 17 September 2020 concerning 1,5-naphthylene diisocyanate [containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm];










—


Opinion of 17 September 2020 concerning 1,5-naphthylene diisocyanate [containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm];










—


Opinion of 8 October 2020 concerning ammonium bromide;










—


Opinion of 8 October 2020 concerning 2,4,6-tri-tert-butylphenol;










—


Opinion of 8 October 2020 concerning pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether;










—


Opinion of 8 October 2020 concerning pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione;










—


Opinion of 8 October 2020 concerning N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram;










—


Opinion of 8 October 2020 concerning 2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether;










—


Opinion of 8 October 2020 concerning 4,4'-isopropylidenediphenol; bisphenol A;










—


Opinion of 8 October 2020 concerning pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene;










—


Opinion of 8 October 2020 concerning dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide;










—


Opinion of 10 December 2020 concerning 4,4'-sulphonyldiphenol; bisphenol S;










—


Opinion of 10 December 2020 2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124;










—


Opinion of 10 December 2020 concerning perfluoroheptanoic acid; tridecafluoroheptanoic acid;










—


Opinion of 10 December 2020 concerning methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate;










—


Opinion of 10 December 2020 concerning 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts;










—


Opinion of 10 December 2020 concerning 6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid;










—


Opinion of 10 December 2020 concerning 6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid;










—


Opinion of 10 December 2020 concerning 1,3,5-triazine-2,4,6-triamine; Melamine;










—


Opinion of 10 December 2020 concerning reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam;










—


Opinion of 10 December 2020 concerning Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents];










—


Opinion of 10 December 2020 concerning divanadium pentaoxide; vanadium pentoxide;










—


Opinion of 10 December 2020 concerning bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide;










—


Opinion of 10 December 2020 concerning a reassessment at the request of the European Commission of the new information on acute inhalation toxicity of 2-butoxyethanol; ethylene glycol monobutyl ether (EGBE)
















(3)


Additional information was received contesting the scientific assessment set out in the RAC opinions of 11 June 2020 concerning 2-ethylhexanoic acid and its salts; of 11 June 2020 concerning a reassessment at the request of the European Commission of the developmental toxicity of N-carboxymethyliminobis (ethylenenitrilo)tetra(acetic acid) (DTPA) and its pentasodium and pentapotassium salts; of 8 October 2020 concerning ammonium bromide; of 10 December 2020 concerning divanadium pentaoxide; of 10 December 2020 concerning a reassessment at the request of the European Commission of the new information on acute inhalation toxicity of 2-butoxyethanol; ethylene glycol monobutyl ether (EGBE); and of 10 December 2020 concerning melamine.












(4)


This additional information was assessed by the Commission and was not found sufficient to cast doubts on the scientific analysis contained in the RAC opinions. It is therefore appropriate to introduce, update or delete the harmonised classification and labelling of the substances concerned on the basis of the assessment made in those opinions.












(5)


Additional information pertaining to the acute inhalation toxicity of silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide was received after the RAC opinion was forwarded to the Commission. The classification of silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide as acute toxic by inhalation Cat. 2, recommended in the RAC opinion of 5 December 2019, should not be included in Annex VI to Regulation (EC) No 1272/2008, as the new scientific information was assessed by the Commission and was found to require further assessment by RAC. However, the classification of this substance as STOT RE 2, recommended in the RAC opinion of 5 December 2019, should be included in Annex VI to Regulation (EC) No 1272/2008, since no new information has been received that would require further assessment for that classification.












(6)


Regulation (EC) No 1272/2008 should therefore be amended accordingly.












(7)


Compliance with the new or updated harmonised classifications should not be required immediately as a certain period of time is necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new or updated classifications and to sell existing stocks subject to the pre-existing regulatory requirements. That period of time is also necessary to allow suppliers sufficient time to take the actions required to ensure continuing compliance with other legal requirements following the changes made under this Regulation. Suppliers should, however, have the possibility to apply the new or updated harmonised classifications, and to adapt the labelling and packaging accordingly, on a voluntary basis before the date of application of this Regulation, to ensure a high level of protection of human health and of the environment and to provide sufficient flexibility to suppliers,





HAS ADOPTED THIS REGULATION:



Article 1

Amendments to Regulation (EC) No 1272/2008

Annex VI to Regulation (EC) No 1272/2008 is amended as set out in the Annex to this Regulation.


Article 2

Entry into force and application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
It shall apply from 23 November 2023.
By way of derogation from the second paragraph of this Article, substances and mixtures may be classified, labelled and packaged in accordance with this Regulation from its date of entry into force.




This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 16 February 2022.


For the Commission


The President

Ursula VON DER LEYEN
            





(1)  
            OJ L 353, 31.12.2008, p. 1.

(2)  The opinions are accessible via the following website: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/. – The opinions of 11 June 2020 and of 10 December 2020 concerning a reassessment at the request of the European Commission are accessible via the following website: https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests




ANNEX
Annex VI to Regulation (EC) No 1272/2008 is amended as follows:






(1)


in Part 3, Table 3 is amended as follows:






(a)


the following entries are inserted:















Index No


Chemical Name


EC No


CAS No


Classification


Labelling


Specific Conc. Limits, M- factors and ATE


Notes




Hazard Class and Category Code(s)


Hazard statement Code(s)


Pictogram, Signal Word Code(s)


Hazard statement Code(s)


Suppl. Hazard statement Code(s)




‘014-052-00-7


silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide


272-697-1


68909-20-6


STOT RE 2


H373 (lungs) (inhalation)


GHS08
Wng


H373 (lungs) (inhalation)


EUH066’


 


 




‘035-005-00-7


ammonium bromide


235-183-8


12124-97-9


Repr. 1B
Lact.
STOT SE 3
STOT RE 1
Eye Irrit. 2


H360FD
H362
H336
H372 (nervous system)
H319


GHS08
GHS07
Dgr


H360FD
H362
H336
H372 (nervous system)
H319’


 


 


 




‘050-032-00-4


dibutyltin bis(2-ethylhexanoate)


220-481-2


2781-10-4


Muta. 2
Repr. 1B
STOT RE 1


H341
H360FD
H372 (immune system)


GHS08
Dgr


H341
H360FD
H372 (immune system)’


 


 


 




‘050-033-00-X


dibutyltin di(acetate)


213-928-8


1067-33-0


Muta 2
Repr. 1B
STOT RE 1


H341
H360FD
H372 (immune system)


GHS08
Dgr


H341
H360FD
H372 (immune system)’


 


 


 




‘052-001-00-0


tellurium


236-813-4


13494-80-9


Repr. 1B
Lact.


H360Df
H362


GHS08
Dgr


H360Df
H362’


 


 


 




‘052-002-00-6


tellurium dioxide


231-193-1


7446-07-3


Repr. 1B
Lact.


H360Df
H362


GHS08
Dgr


H360Df
H362’


 


 


 




‘056-005-00-3


barium diboron tetraoxide


237-222-4


13701-59-2


Repr. 1B
Acute Tox. 4
Acute Tox. 3


H360FD
H332
H301


GHS08
GHS06
Dgr


H360FD
H332
H301


 


inhalation:
ATE = 1,5 mg/L (dusts or mists)
oral:
ATE = 100 mg/kg bw’


 




‘601-097-00-8


Propylbenzene


203-132-9


103-65-1


Flam. Liq. 3
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2


H226
H304
H335
H411


GHS02
GHS08
GHS07
GHS09
Dgr


H226
H304
H335
H411’


 


 


 




‘603-243-00-6


2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol


253-057-0


36483-57-5; 1522-92-5


Carc. 1B
Muta. 2


H350
H341


GHS08
Dgr


H350
H341’


 


 


 




‘604-096-00-0


piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether


200-076-7


51-03-6


STOT SE 3
Eye Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1


H335
H319
H400
H410


GHS07
GHS09
Wng


H335
H319
H410


EUH066


M = 1
M = 1’


 




‘604-097-00-6


2,4,6-tri-tert-butylphenol


211-989-5


732-26-3


Repr. 1B
Acute Tox. 4
STOT RE 2
Skin Sens. 1B


H360D
H302
H373 (liver)
H317


GHS08
GHS07
Dgr


H360D
H302
H373 (liver)
H317


 


oral:
ATE = 500 mg/kg bw’


 




‘604-098-00-1


4,4'-sulphonyldiphenol; bisphenol S


201-250-5


80-09-1


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




‘606-153-00-5


benzophenone


204-337-6


119-61-9


Carc. 1B


H350


GHS08
Dgr


H350’


 


 


 




‘606-154-00-0


quinoclamine (ISO); 2-amino-3-chloro-1,4-naphthoquinone


220-529-2


2797-51-5


Carc. 2
Repr. 2
Acute Tox. 4
STOT RE 2
Eye Irrit. 2
Skin Sens. 1A
Aquatic Acute 1
Aquatic Chronic 1


H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H361d
H302
H373 (blood system, kidneys)
H319
H317
H410


 


oral:
ATE = 500 mg/kg bw
M = 10
M = 10’


 




‘607-756-00-6


exo-1,7,7-trimethylbicyclo[2.2.1]hept-2-yl acrylate; isobornyl acrylate


227-561-6


5888-33-5


Skin Sens. 1A


H317


GHS07
Wng


H317’


 


 


 




‘607-757-00-1


daminozide (ISO); 4-(2,2-dimethylhydrazino)-4-oxobutanoic acid; N-dimethylaminosuccinamic acid


216-485-9


1596-84-5


Carc. 2


H351


GHS08
Wng


H351’


 


 


 




‘607-758-00-7


4,4'-oxydi(benzenesulphonohydrazide)


201-286-1


80-51-3


Self-react. D
Aquatic Acute 1
Aquatic Chronic 1


H242
H400
H410


GHS02
GHS09
Dgr


H242
H410


 


M = 1
M = 1’


 




‘607-759-00-2


toluene-4-sulphonohydrazide


216-407-3


1576-35-8


Self-react. D


H242


GHS02
Dgr


H242’


 


 


 




‘607-760-00-8


2-[N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino]ethyl acetate; C.I. Disperse Blue 124


239-203-6


15141-18-1


Skin Sens. 1A


H317


GHS07
Wng


H317


 


Skin Sens. 1A; H317: C ≥ 0,001 %’


 




‘607-761-00-3


Perfluoroheptanoic acid; tridecafluoroheptanoic acid


206-798-9


375-85-9


Repr. 1B
STOT RE 1


H360D
H372 (liver)


GHS08
Dgr


H360D
H372 (liver)’


 


 


 




‘607-762-00-9


methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate


-


283159-90-0


Carc. 2
Aquatic Chronic 2


H351
H411


GHS08
GHS09
Wng


H351
H411’


 


 


 




‘607-763-00-4


6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts


-


-


Repr. 1B
Eye Irrit. 2


H360FD
H319


GHS08
GHS07
Dgr


H360FD
H319’


 


 


 




‘607-764-00-X


6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid


-


2156592-54-8


Repr. 1B
Eye Irrit. 2


H360FD
H319


GHS08
GHS07
Dgr


H360FD
H319’


 


 


 




‘607-765-00-5


6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid


-


-


Repr. 1B


H360FD


GHS08
Dgr


H360FD’


 


 


 




‘613-341-00-0


clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine


277-728-2


74115-24-5


Aquatic Chronic 1


H410


GHS09
Wng


H410


 


M = 1’


 




‘613-342-00-6


theophylline; 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione


200-385-7


58-55-9


Repr. 1B


H360D


GHS08
Dgr


H360D’


 


 


 




‘613-343-00-1


pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether


-


179101-81-6


Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H317
H400
H410


GHS07
GHS09
Wng


H317
H410


 


M = 1 000 
M = 100’


 




‘613-344-00-7


Pyridine-2-thiol 1-oxide, sodium salt; pyrithione sodium; sodium pyrithione


223-296-5;
240-062-8


3811-73-2;
15922-78-8


Acute Tox. 3
Acute Tox. 3
Acute Tox. 4
STOT RE 1
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 2


H331
H311
H302
H372 (nervous system)
H315
H319
H317
H400
H411


GHS06
GHS08
GHS09
Dgr


H331
H311
H302
H372 (nervous system)
H315
H319
H317
H410


EUH070


inhalation:
ATE = 0,5 mg/L (dusts or mists)
dermal:
ATE = 790 mg/kg bw
oral:
ATE = 500 mg/kg bw
M = 100’


 




‘613-345-00-2


1,3,5-triazine-2,4,6-triamine;
melamine


203-615-4


108-78-1


Carc. 2
STOT RE 2


H351
H373 (urinary tract)


GHS08
Wng


H351
H373 (urinary tract)’


 


 


 




‘615-046-00-2


1,3-bis(1-isocyanato-1-methylethyl)benzene; [m-TMXDI]


220-474-4


2778-42-9


Resp. Sens. 1
Skin Sens. 1A


H334
H317


GHS08
Dgr


H334
H317’


 


 


 




‘615-047-00-8


1,3-bis(isocyanatomethyl)benzene; [m-XDI]


222-852-4


3634-83-1


Resp. Sens. 1
Skin Sens. 1A


H334
H317


GHS08
Dgr


H334
H317


 


Skin Sens. 1A; H317: C ≥ 0,001 %’


 




‘615-048-00-3


2,4,6-triisopropyl-m-phenylene diisocyanate


218-485-4


2162-73-4


Resp. Sens. 1
Skin Sens. 1


H334
H317


GHS08
Dgr


H334
H317’


 


 


 




‘615-049-00-9


1,5-naphthylene diisocyanate
[containing < 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]


221-641-4


3173-72-6


STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3


H335
H315
H319
H334
H317
H412


GHS07
GHS08
Dgr


H335
H315
H319
H334
H317
H412’


 


 


 




‘615-050-00-4


1,5-naphthylene diisocyanate
[containing ≥ 0,1 % (w/w) of particles with an aerodynamic diameter of below 50 μm]


221-641-4


3173-72-6


Acute Tox. 2
STOT SE 3
Skin Irrit. 2
Eye Irrit. 2
Resp. Sens. 1
Skin Sens. 1A
Aquatic Chronic 3


H330
H335
H315
H319
H334
H317
H412


GHS06
GHS08
Dgr


H330
H335
H315
H319
H334
H317
H412


 


inhalation:
ATE = 0,27 mg/L (dusts or mists)’


 




‘616-237-00-3


fluopicolide (ISO); 2,6-dichloro-N-[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide


-


239110-15-7


Repr. 2


H361d


GHS08
Wng


H361d’


 


 


 




‘616-238-00-9



N-(2-nitrophenyl)phosphoric triamide


477-690-9


874819-71-3


Repr. 1B
STOT RE 2


H360Fd
H373 (kidneys)


GHS08
Dgr


H360Fd
H373 (kidneys)’


 


 


 




‘616-239-00-4



N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide; isoflucypram


-


1255734-28-1


Repr. 2
Acute Tox. 4
Skin Sens. 1B
Aquatic Acute 1
Aquatic Chronic 1


H361f
H332
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H361f
H332
H317
H410


 


inhalation:
ATE = 2,2 mg/L (dusts or mists)
M = 10
M = 1’


 




‘616-240-00-X


Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9RS)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [≥ 78 % syn isomers ≤ 15 % anti isomers relative content]; isopyrazam


-


881685-58-1


Carc. 2
Repr. 1B
Skin Sens. 1B
Aquatic Acute 1 Aquatic Chronic 1


H351
H360D
H317
H400
H410


GHS08
GHS07
GHS09
Dgr


H351
H360D
H317
H410


 


Repr. 1B; H360D:
C ≥ 3 %
M = 10
M = 10’


 




‘650-058-00-1


Margosa, ext. [from the kernels of Azadirachta indica extracted with water and further processed with organic solvents]


283-644-7


84696-25-3


Repr. 2
Skin Sens. 1
Aquatic Chronic 1


H361d
H317
H410


GHS08
GHS07
GHS09
Wng


H361d
H317
H410


 


M = 10’


 














(b)


the entries corresponding to index numbers 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 are replaced by the following entries respectively:















Index No


Chemical Name


EC No


CAS No


Classification


Labelling


Specific Conc. Limits, M- factors and ATE


Notes




Hazard Class and Category Code(s)


Hazard statement Code(s)


Pictogram, Signal Word Code(s)


Hazard statement Code(s)


Suppl. Hazard statement Code(s)




‘014-001-00-9


trichlorosilane


233-042-5


10025-78-2


Flam. Liq. 1
Water-react. 1
Acute Tox. 3
Acute Tox. 4
Skin Corr. 1A
Eye Dam. 1


H224
H260
H331
H302
H314
H318


GHS02
GHS06
GHS05
Dgr


H224
H260
H331
H302
H314


EUH014
EUH029
EUH071


inhalation:
ATE = 7,6 mg/L (vapour)
oral:
ATE = 1 000  mg/kg bw’


 




‘023-001-00-8


divanadium pentaoxide; vanadium pentoxide


215-239-8


1314-62-1


Muta. 2
Carc. 1B
Repr. 2
Lact.
Acute Tox. 3
Acute Tox. 2
STOT SE 3
STOT RE 1
Aquatic Chronic 2


H341
H350
H361fd
H362
H301
H330
H335
H372 (respiratory tract, inhalation)
H411


GHS06
GHS08
GHS09
Dgr


H341
H350
H361fd
H362
H301
H330
H335
H372 (respiratory tract, inhalation)
H411


 


inhalation:
ATE = 0,05 mg/L (dusts or mists)
oral:
ATE = 220 mg/kg bw’


 




‘601-024-00-X


Cumene


202-704-5


98-82-8


Flam. Liq. 3
Carc. 1B
Asp. Tox. 1
STOT SE 3
Aquatic Chronic 2


H226
H350
H304
H335
H411


GHS02
GHS08
GHS07
GHS09
Dgr


H226
H350
H304
H335
H411’


 


 


 




‘603-014-00-0


2-butoxyethanol; ethylene glycol monobutyl ether


203-905-0


111-76-2


Acute Tox. 3
Acute Tox. 4
Skin Irrit. 2
Eye Irrit. 2


H331
H302
H315
H319


GHS06
Dgr


H331
H302
H315
H319


 


inhalation:
ATE = 3 mg/L (Vapours)
oral:
ATE = 1 200  mg/kg bw’


 




‘603-107-00-6


2-(2-methoxyethoxy)ethanol; diethylene glycol monomethyl ether


203-906-6


111-77-3


Repr. 1B


H360D


GHS08
Dgr


H360D


 


Repr. 1B; H360D: C ≥ 3 %’


 




‘604-030-00-0


4,4'-isopropylidenediphenol; bisphenol A


201-245-8


80-05-7


Repr. 1B
STOT SE 3
Eye Dam. 1
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H360F
H335
H318
H317
H400
H410


GHS08
GHS07
GHS05
GHS09
Dgr


H360F
H335
H318
H317
H410


 


M = 1
M = 10’


 




‘607-111-00-9


2-ethyl-2-[[(1-oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2-bis(acryloyloxymethyl)butyl acrylate;
trimethylolpropane triacrylate


239-701-3


15625-89-5


Carc. 2
Skin Irrit. 2
Eye Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1


H351
H315
H319
H317
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H315
H319
H317
H410


 


M = 1
M = 1


D’




‘607-230-00-6


2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex


-


-


Repr. 1B


H360D


GHS08
Dgr


H360D’


 


 


 




‘607-253-00-1


cyfluthrin (ISO); α-cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate


269-855-7


68359-37-5


Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1


H362
H330
H300
H370 (nervous system)
H400
H410


GHS06
GHS08
GHS09
Dgr


H362
H330
H300
H370 (nervous system)
H410


 


inhalation:
ATE = 0,14 mg/L (dusts or mists)
oral:
ATE = 14 mg/kg bw
M = 1 000 000 
M = 1 000 000 ’


 




‘607-254-00-7


beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate


-


1820573-27-0


Lact.
Acute Tox. 2
Acute Tox. 2
STOT SE 1
Aquatic Acute 1
Aquatic Chronic 1


H362
H330
H300
H370 (nervous system)
H400
H410


GHS06
GHS08
GHS09
Dgr


H362
H330
H300
H370 (nervous system)
H410


 


inhalation:
ATE = 0,081 mg/L (dusts or mists)
oral:
ATE = 11 mg/kg bw
M = 1 000 000 
M = 1 000 000 ’


 




‘607-734-00-6


pentapotassium 2,2',2",2"',2""-(ethane-1,2-diylnitrilo)pentaacetate


404-290-3


7216-95-7


Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2


H360D
H332
H373 (inhalation)
H319


GHS08
GHS07
Dgr


H360D
H332
H373 (inhalation)
H319


 


Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’


 




‘607-735-00-1



N-carboxymethyliminobis(ethylenenitrilo)tetra(acetic acid)


200-652-8


67-43-6


Repr. 1B
Acute Tox. 4
STOT RE 2
Eye Irrit. 2


H360D
H332
H373 (inhalation)
H319


GHS08
GHS07
Dgr


H360D
H332
H373 (inhalation)
H319


 


Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’


 




‘607-736-00-7


pentasodium (carboxylatomethyl)iminobis(ethylenenitrilo)tetraacetate


205-391-3


140-01-2


Repr. 1B
Acute Tox. 4
STOT RE 2


H360D
H332
H373 (inhalation)


GHS08
GHS07
Dgr


H360D
H332
H373 (inhalation)


 


Repr. 1B; H360D: C ≥ 3 %
inhalation:
ATE = 1,5 mg/L (dusts or mists)’


 




‘608-032-00-2


acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N’-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine


-


135410-20-7 160430-64-8


Repr. 2
Acute Tox. 3
Aquatic Chronic 1
Aquatic Acute 1


H361d
H301
H410
H400


GHS08
GHS06
GHS09
Dgr


H361d
H301
H410


 


oral:
ATE = 140 mg/kg bw
M = 10
M = 10’


 




‘609-042-00-X


pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene


254-938-2


40487-42-1


Repr. 2
Aquatic Acute 1
Aquatic Chronic 1


H361d
H400
H410


GHS08
GSH09
Wng


H361d
H410


 


M = 100
M = 10’


 




‘613-012-00-1


bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide


246-585-8


25057-89-0


Repr. 2
Acute Tox. 4
Eye Irrit. 2
Skin Sens. 1


H361d
H302
H319
H317


GHS08
GHS07
Wng


H361d
H302
H319
H317


 


oral: ATE = 1 600  mg/kg bw’


 




‘616-164-00-7


dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide


 


149961-52-4


Carc. 2
Repr. 2
Acute Tox. 4
Aquatic Acute 1
Aquatic Chronic 1


H351
H361d
H332
H400
H410


GHS08
GHS07
GHS09
Wng


H351
H361d
H332
H410


 


inhalation:
ATE = 1,3 mg/L (dusts or mists)
M = 100
M = 100’


 














(c)


the entry corresponding to index number 615-007-00-X is deleted.